ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,445.80
0.21%
Dow Jones
39,908.00
0.88%
Gold vs US Dollar
2,386.83
1.34%
Brent Oil
82.715
0.20%
Bitcoin
65,948.69
7.16%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Knight Therapeutics Inc (GUD)

  7. Knight Therapeutics Inc (GUD) News

Knight Therapeutics (GUD)

Knight Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:GUD
DateTimeSourceHeadlineSymbolCompany
10/08/202316:00AllPennyStocks.comTrading For This Specialty Pharma Company is up Following Second Quarter ResultsTSX:GUDKnight Therapeutics Inc
13/05/202114:38PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - GUDTSX:GUDKnight Therapeutics Inc
13/05/202114:37PR Newswire (Canada)IIROC Trade Resumption - GUDTSX:GUDKnight Therapeutics Inc
13/05/202113:25PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - GUDTSX:GUDKnight Therapeutics Inc
13/05/202113:24PR Newswire (Canada)IIROC Trading Halt - GUDTSX:GUDKnight Therapeutics Inc
03/05/202111:00PR Newswire (Canada)Maverix Private Equity Announces Team AdditionsTSX:GUDKnight Therapeutics Inc
03/05/202111:00PR Newswire (US)Maverix Private Equity Announces Team AdditionsTSX:GUDKnight Therapeutics Inc
11/12/202022:15PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite IndexTSX:GUDKnight Therapeutics Inc
11/12/202022:15PR Newswire (Canada)S&P Dow Jones Indices annonce des modifications à l'indice composé S&P/TSXTSX:GUDKnight Therapeutics Inc
08/01/202013:00PR Newswire (US)Knight Partners With Debiopharm for the Commercialization of Trelstar® in CanadaTSX:GUDKnight Therapeutics Inc
18/06/201922:00PR Newswire (US)Medimetriks Pharmaceuticals Focuses on Advancing MM36 (difamilast) Through Phase 3 Trials; Extinguishes Debt Owed to Knight T...TSX:GUDKnight Therapeutics Inc
29/04/201913:45PR Newswire (Canada)Medison Urges Fellow Shareholders to Bring Positive Change to Knight Therapeutics by Voting for All Six of Medison's Highly Q...TSX:GUDKnight Therapeutics Inc
25/04/201915:21PR Newswire (Canada)Leading Independent Proxy Advisory Firm ISS Recommends Change at Knight TherapeuticsTSX:GUDKnight Therapeutics Inc
18/04/201914:00PR Newswire (Canada)Medison Issues Presentation to Knight ShareholdersTSX:GUDKnight Therapeutics Inc
17/04/201912:00PR Newswire (Canada)Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutic...TSX:GUDKnight Therapeutics Inc
16/04/201913:30PR Newswire (Canada)Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-S...TSX:GUDKnight Therapeutics Inc
10/04/201913:39PR Newswire (Canada)Medison Disappointed that Knight Therapeutics has Resorted to Blatant Misrepresentations to Avoid ScrutinyTSX:GUDKnight Therapeutics Inc
08/04/201913:00PR Newswire (Canada)Medison Files Proxy Circular, Offers Knight Therapeutics Shareholders Truly Independent, Unconflicted Directors and Comprehen...TSX:GUDKnight Therapeutics Inc
01/04/201913:00PR Newswire (Canada)Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Cre...TSX:GUDKnight Therapeutics Inc
18/02/201913:30PR Newswire (US)Knight Signs GUD (Bueno) Latin American Strategic Funding Deal with Moksha8TSX:GUDKnight Therapeutics Inc
19/03/201810:30PR Newswire (US)Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in CanadaTSX:GUDKnight Therapeutics Inc
08/02/201814:21PR Newswire (US)60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria DrugTSX:GUDKnight Therapeutics Inc
08/02/201814:03PR Newswire (US)60° Pharmaceuticals (60P) Receives Priority Review Designation For Malaria DrugTSX:GUDKnight Therapeutics Inc
04/01/201814:45PR Newswire (US)60 Degrees Pharmaceuticals Fast Tracked For Malaria DrugTSX:GUDKnight Therapeutics Inc
18/12/201714:00PR Newswire (US)60° Pharmaceuticals (60P) Submits New Drug Application to US FDA for Antimalarial Drug TafenoquineTSX:GUDKnight Therapeutics Inc
14/08/201722:30MarketwiredSynergy CHC Corp. Announces Second Quarter 2017 ResultsTSX:GUDKnight Therapeutics Inc
13/06/201713:03PR Newswire (Canada)Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid...TSX:GUDKnight Therapeutics Inc
13/06/201713:03PR Newswire (US)Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid...TSX:GUDKnight Therapeutics Inc
09/12/201623:17PR Newswire (Canada)Indices S&P Dow Jones annonce des modifications à certains indices canadiens S&P/TSXTSX:GUDKnight Therapeutics Inc
22/03/201611:59PR Newswire (US)Profounda, Inc. launches Impavido® (miltefosine), the first and only oral Rx treatment for visceral, mucosal and cutaneous l...TSX:GUDKnight Therapeutics Inc
 Showing the most relevant articles for your search:TSX:GUD

Your Recent History

COIN
MBTCOBTC
Minibitcoin
BIT
UB7RU1
Unicredit Bank
COIN
SCCPUST
S.C. Corinthians Fan Token
NYSE
NGVT
Ingevity
BIT
P1INK6
BNP Paribas Issuance
BIT
UC1TKV
Unicredit Bank
LSE
D4H
Downing Four Vct
LSE
0KKA
LSE
CFTA
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved